— Know what they know.
Not Investment Advice

AKRO NASDAQ

Akero Therapeutics, Inc.
1W: +0.3% 1M: +1.1% 3M: +26.4% 1Y: +84.0% 3Y: +20.2% 5Y: +93.0%
$54.65
Last traded 2025-12-09 — delisted
NASDAQ · Healthcare · Biotechnology · $4.5B mcap · 71M float · 3.60% daily turnover · Short 26% of daily vol

Cash Flow Trends

Operating Cash Flow
-$230M -58.3% ▼
Capital Expenditures
$999K +0.0% ▲
Free Cash Flow
-$231M -58.3% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$106M +776.5% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
— Operating Activities —
Net Income-$79M-$101M-$112M-$152M-$252M
Depreciation & Amort.$17K$41K$43K$29K$18K
Stock-Based Comp.$6M$10M$23M$21M$30M
Change in Working Capital$2M$10M-$4M-$7M$3M
Other Non-Cash Items$196K$203K$689K-$8M-$11M
Operating Cash Flow-$71M-$80M-$93M-$145M-$230M
— Investing Activities —
Capital Expenditures-$148K$0$0$0-$999K
Acquisitions (Net)$10K$0$0$0$0
Investment Purchases-$115M-$44M-$101M-$433M-$516M
Investment Sales$105M$86M$38M$210M$407M
Other Investing-$10K$0$0$0$0
Investing Cash Flow-$10M$42M-$64M-$224M-$110M
— Financing Activities —
Net Debt Issuance$0$0$10M$15M$10M
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$553K$0$4M$3M$13M
Financing Cash Flow$203M$602K$256M$353M$446M
Net Change in Cash$123M-$37M$99M-$16M$106M
Cash End of Period$187M$151M$250M$234M$340M
Free Cash Flow-$71M-$80M-$93M-$145M-$231M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms